Health Professional Radio - Podcast

Dr. Raymond Douglas, an oculoplastic surgeon, discusses the approval of TEPEZZA™ (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED), the first and only FDA-approved medicine for the treatment of TED. The FDA approval of TEPEZZA™ is supported by a robust body of clinical evidence, including statistically significant, positive results from the Phase 2 clinical study, as well as the Phase 3 confirmatory clinical study OPTIC. Dr. Douglas previously presented at the American College of Rheumatology (ACR) 2019 annual meeting, sharing integrated, pooled phase 2/phase 3 clinical study data that further substantiates that teprotumumab improves the debilitating effects of active TED, including proptosis (eye bulging), diplopia (double vision), quality of life (QoL) and clinical activity score (CAS). He is joined by Wendy a participant in the TEPEZZA™ trial who saw an improvement in her eye bulging among other symptoms.